Khaled Musallam/LinkedIn
Nov 20, 2025, 16:47
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Priviliged to be working with my friend Prof.Humaid Al-Shamsi to build on the strong foundations of BCI and lead the expansion of hematology services across the network, including dedicated programs in both classical (benign) and malignant hematology, and advanced cell and gene therapies through innovative clinical trials and strategic international partnerships with industry innovators.”
Stay updated with Hemostasis Today.
-
Apr 1, 2026, 17:47Akshaya Sharon: Qfitlia as a Shift in Treatment Strategy for Hemophilia A and B
-
Apr 1, 2026, 17:21Antonio Pineda Guerrero: Elevated Lp(a) Raises VTE Risk But Only in the Right Hormonal Context
-
Apr 1, 2026, 17:19Shaik Nayeem Uddin: Clopidogrel and Omeprazole Combination Can Quietly Reduce A Life-Saving Effect
-
Apr 1, 2026, 17:18John Abraham: Breaking the ‘Bleeding Disorder’ Myth About Cirrhosis and Coagulation
-
Apr 1, 2026, 17:17Heghine Khachatryan: Linking Coagulation, Inflammation, and Neurodegeneration In Neuro-Hemostasis Axis
-
Apr 1, 2026, 17:15Chokri Ben Lamine: Differentiating Reactive from Clonal Causes in Adult Neutrophilia
-
Apr 1, 2026, 16:05Gregory Piazza: Discussing the 2026 AHA/ACC Guidelines for Acute PE at ACC.26
-
Apr 1, 2026, 15:31Simon Senanu: A Stepwise Laboratory Approach for aPTT Prolongation
-
Apr 1, 2026, 15:30Liza Bulsara: Early Clinical Warning Signs of Pediatric Hematologic Disorders